(4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl) propionic acid | 218911-02-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl) propionic acid
• 英文别名: 3-[4-[2-[[(2R)-2-(6-aminopyridin-3-yl)-2-hydroxyethyl]amino]ethoxy]phenyl]propanoic acid
• CAS: 218911-02-5
• 化学式: C₁₈H₂₃N₃O₄
• 分子量: 345.398
• InChiKey: SWYGYYGZBQYETO-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Compounds for the treatment of obesity
  申请人：——

  公开号：US20010039277A1

  公开（公告）日：2001-11-08

  NPY antagonists, methods of using such NPY antagonists and pharmaceutical compositions containing such NPY antagonists. The NPY antagonists are useful for the treatment of NPY mediated disease/conditions including obesity.

  NPY拮抗剂，使用此类NPY拮抗剂的方法以及含有此类NPY拮抗剂的药物组合物。这些NPY拮抗剂对于治疗由NPY介导的疾病/症状，包括肥胖症，是有用的。
• Triamide-substituted heterobicyclic compounds
  申请人：Pfizer Inc.

  公开号：US20030187053A1

  公开（公告）日：2003-10-02

  The invention relates to triamide MTP/ApoB inhibitors of the formula 1 1 wherein R 1 -R 8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.

  本发明涉及三酰胺MTP/ApoB抑制剂，其化学公式为1，其中R1-R8如说明书所述，以及包含这些化合物的药物组合物及其用途，以及制备这些化合物的方法。本发明的化合物可用于治疗肥胖和脂质紊乱。
• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• [EN] THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF<br/>[FR] AGONISTE DU RÉCEPTEUR DES HORMONES THYROÏDIENNES ET SON UTILISATION
  申请人：METABASIS THERAPEUTICS INC

  公开号：WO2017184811A1

  公开（公告）日：2017-10-26

  A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or thyroid hormone axis.

  描述了一种甲状腺激素受体激动剂及其在治疗与甲状腺激素受体β相关的疾病中的应用。该化合物可以有效降低胆固醇，对心脏或甲状腺激素轴的不良影响最小或没有。
• Malonamic acids and derivatives thereof as thyroid receptor ligands
  申请人：——

  公开号：US20010051657A1

  公开（公告）日：2001-12-13

  The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula 1, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders. 1

  本发明涉及新型甲状腺受体配体，更具体地涉及Formula 1的马隆酰胺酸及其衍生物，可用于治疗肥胖、超重症、高脂血症、青光眼、心律失常、皮肤疾病、甲状腺疾病、甲状腺功能减退、甲状腺癌及相关疾病，如糖尿病、动脉粥样硬化、高血压、冠心病、充血性心力衰竭、高胆固醇血症、抑郁症、骨质疏松症和脱发。本发明还提供了用于治疗此类疾病和疾病的方法、药物组合物和试剂盒。